Primary tumor phenotypic and genotypic characteristics may be different from those characteristics in cells, which have disseminated and implanted in distant sites. Thus the selection of specific treatments based on the characteristics of the primary tumor may not be the most appropriate. HER2 expression in bone marrow micrometastasis has been reported to be up to 60% in comparison with the 20% expressed in primary breast tumors [14] . Similarly, HER-2-positive prostate cells are associated with resistance to androgen blockade but not diethylstilbestrol [15] . In colon cancer, KRAS and BRAF mutations detected in primary and metastatic cancer are used as predictive markers for anti-EGFR therapy. However, there is discordance between KRAS mutations in CTCs and primary tumors; there are more mutations in CTCs in stage I and II patients and less in stage IV patients. Furthermore, the more aggressive KRAS codon 12 mutations were more frequently detected than the KRAS codon 13 mutations in CTCs [16] .
Thus the use of MRD to determine specific treatments may improve treatment results. The repeated use of MRD classification would allow changes in treatment before the appearance of metastatic disease. Changes in tumor cell sensitivity by clonal evolution or clonal selection detected during follow-up would identify patients at the risk of relapse. Serial sampling of CTCs has shown changes in the KRAS mutational status during treatment and thus predict patient response to targeted therapy [17] .
This leads to another important question: when should samples be taken? CTCs are rapidly cleared from the circulation, mostly within 24 h [18] . There is no information on the time scale of elimination of micrometastasis. As for tfDNA, the question of how long tfDNA continues to be released from dead and dying tumour cells after treatment is not known.
More recently, differing types of MRD have been identified; those patients with CTCs are at early risk of relapse whereas those with only bone marrow micrometastasis of late relapse [12, 19] . It appears that patients with CTCs have a more aggressive disease than those with only DTCs; this has been reported in esophageal cancer [20] , colon cancer [12] , prostate cancer [19] , pancreatic cancer [11] and breast cancer [21] .
This raises the interesting question of do all MRDs need to be treated? With increasingly sensitive molecular techniques to detect tumor cells, it may be that below a certain tumor load, the body is able to control tumor cell proliferation. This is the concept of dormancy. However, with time, due to changes in the tumor cell or stromal microenvironment, the cells begin to proliferate and disseminate, giving rise to metastatic diseases. This has been reported in patients with chronic myeloid leukemia post bone marrow transplant, whereby PCT-detected tumor cells are found in patients in 'complete' remission years after transplant [22] . Thus a form of active surveillance may be more effective, starting treatment when CTCs appear. This leads to the next question: do all MRDs need to be eradicated? In myeloma, treatment is continued until the paraprotein is stable, the 'plateau' phase of the disease. In patients achieving plateau, active treatment is stopped and maintenance treatment such as thalidomide, lenolidamide and/or bisphosphonates is used until the paraprotein levels start to rise. If CTCs are eradicated, leaving only bone marrow DTCs, is this equivalent to plateau phase in myeloma? Bisphosphonates have been reported to eliminate CTCs and DTCs [23] [24] [25] [26] and as such could have a role in extending the 'plateau phase' of solid tumors.
Combined methods of detection and characterization may yield more clinically meaningful data, for example CTCs with DNA/RNA analysis permits the morphological confirmation of a tumour cell with a specific marker, for example BRAF to define specific treatments. Due to the heterogeneity of tumor cells, not all tumour cells will be positive for a given marker; for example, HER-2, BRAF; thus tfDNA negative for BRAF does not imply the absence of CTCs but the absence of CTCs positive for BRAF. This would also permit the identification of clonal selection post-treatment, such as ARv7 variants in prostate cancer patients and the selection of androgen blockade [27] . Single CTC sequencing shows the genetic heterogeneity of these cancer cells and has been reported to identify therapeutic resistance, multiple mutations in the ALK-independent pathways and the RTK-KRAS genes seen with crizotinib and lorlatinib resistance in patients with non-small-cell lung cancer [28] .
At present, there is not a single 'gold-standard' method for the detection of CTCs and/or DTCs however, the detection of CTCs and DTCs overcomes many of the limits of surgical biopsies. Both blood and bone marrow can be repeatedly sampled for the detection of cancer cells thus detecting changes in the phenotypic and genotypic characteristics before the appearance of clinical disease.
In summary, it is important to define and understand what biomarkers mean, both positive and negative results, and the purpose of their use. Their possible role in the detection of MRD after primary curative therapy identifies high-risk patients in whom additional treatment is most likely to be beneficial. A possible role during follow-up is the early detection of treatment resistence enabling changes in treatment before the appearence of clinical metastasis.
When detecting MRD, it is important to recognize that there are subtypes and it may not be necessary to eradicate all subtypes of MRD in order to produce clinical benefits. In the real world, health budgets do not allow high technology, high cost tests, bone marrow sampling with immunocytochemistry or detection of circulating tumor cells using density gradient differential centrifugation and immunocytochemistry or FISH may be more readily available in district hospitals. Equally important are results based on a positive/negative or yes/no decision-making choice and thus making the oncologist's job easier.
